Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lomefloxacin aspartate is a fluoroquinolone antibiotic and a small molecule derivative of lomefloxacin. It functions as a broad-spectrum antimicrobial agent by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. This inhibition leads to double-stranded DNA breaks and bacterial cell death. Developed primarily to enhance water solubility and stability compared to the hydrochloride salt, the aspartate formulation is particularly suited for intravenous or intramuscular injection. It is indicated for the treatment of various bacterial infections, including chronic bronchitis, complicated and uncomplicated urinary tract infections (UTIs), and respiratory, gastrointestinal, and genitourinary tract infections. It is also utilized prophylactically to prevent UTIs in patients undergoing transrectal or transurethral surgical procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lomefloxacin aspartate.